Phase Ib dose-escalation study of MetMAb, a monovalent antagonist antibody to the receptor MET, in combination with bevacizumab in patients with locally advanced or metastatic solid tumors.

**Sub-category:**
Phase I Studies

**Category:**
Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

**Meeting:**
2010 ASCO Annual Meeting

**Session Type and Session Title:**
This abstract will not be presented at the 2010 ASCO Annual Meeting but has been published in conjunction with the meeting.

**Abstract No:**
e13050

**Citation:**
J Clin Oncol 28, 2010 (suppl; abstr e13050)

**Author(s):**
R. A. Moss, J. G. Bothos, E. Filvaroff, M. Merchant, S. Eppler, W. Yu, K. Harris, P. Scott, J. M. Mehnert, P. H. Patel; The Cancer Institute of New Jersey, New Brunswick, NJ; Genentech, South San Francisco, CA; Cancer Institute of New Jersey, New Brunswick, NJ

**Abstract Disclosures**

**Faculty & Discussant Disclosures**

**Annual Meeting Planning Committee Disclosures**

**Abstract:**

**Background:** Crosstalk between the Met and vascular endothelial growth factor (VEGF) pathways may be important during tumorigenesis. Aberrant activation of the HGF/Met pathway may promote angiogenesis via tumor cell secretion of angiogenic factors or directly activating endothelial cells. The combination of Met and VEGF inhibition resulted in enhanced antitumor activity in multiple preclinical models than either treatment alone. MetMAb is a recombinant, humanized, monovalent (one-armed) monoclonal antibody antagonist of HGF-induced Met signaling. In phase Ia, MetMAb was generally well tolerated up to 30 mg/kg IV Q3W. Herein, we describe results from a phase Ib study in which we tested MetMAb in combination with bevacizumab. **Methods:** The phase Ib trial tested the combination of MetMAb with bevacizumab in two cohorts: 3 patients in cohort 1 received MetMAb, 10 mg/kg, and bevacizumab, 15 mg/kg, IV Q3W; and 6 patients in cohort 2 received MetMAb,15 mg/kg, and bevacizumab,15 mg/kg IV Q3W. Pre- and post-dose sera were collected for evaluation of pharmacodynamic (PD) biomarkers that could be affected by inhibition of Met and/or VEGF signaling. **Results:** The combination of MetMAb with bevacizumab was generally well tolerated at all doses tested. No Gr3-5 drug-related toxicities were observed. One DLT of Gr1 hemoptysis in cohort 2 was observed in a patient who had central-necrosis of pulmonary metastases. Gr2 drug-related toxicities included peripheral edema and hypoalbuminemia. The most frequently observed toxicities (>30 %) included fatigue and increased weight. The best response was stable disease, with 3 patients receiving ≥ 6 cycles. PD biomarker data will be discussed. MetMAb PK was similar to that from phase Ia and no apparent interaction with bevacizumab was observed. **Conclusions:** This phase Ib trial demonstrated that the combination of MetMAb and bevacizumab is generally safe and well tolerated at the recommended dose of 15mg/kg Q3W for each agent.
**Associated Presentation(s):**

No items found.

**Other Abstracts in this Sub-Category:**

1. **Use of a human ribonuclease variant, QBI-139, for the treatment of cancer.**
   
   Meeting: 2010 ASCO Annual Meeting  
   Abstract No: TPS162  
   First Author: L. E. Strong  
   Category: Developmental Therapeutics - Clinical Pharmacology and Immunotherapy - Phase I Studies

2. **Phase I study of dasatinib in combination with bevacizumab in advanced solid tumors.**
   
   Meeting: 2010 ASCO Annual Meeting  
   Abstract No: TPS163  
   First Author: G. Kim  
   Category: Developmental Therapeutics - Clinical Pharmacology and Immunotherapy - Phase I Studies

3. **A multicenter, open-label phase Ib/II study to assess the safety and clinical activity of intravenous combretastatin A1 diphosphate (OXi4503) as monotherapy in subjects with primary or secondary hepatic tumor burden.**
   
   Meeting: 2010 ASCO Annual Meeting  
   Abstract No: TPS164  
   First Author: P. N. Mainwaring  
   Category: Developmental Therapeutics - Clinical Pharmacology and Immunotherapy - Phase I Studies

**More...**

**Abstracts by R. A. Moss:**

1. **Is there a therapeutic benefit for patients participating in modern phase I trials?**
   
   Meeting: 2011 ASCO Annual Meeting  
   Abstract No: 2523  
   First Author: M. N. Stein  
   Category: Developmental Therapeutics - Clinical Pharmacology and Immunotherapy - Other

2. **Phase I trial of veliparib, (ABT-888), a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors.**
   
   Meeting: 2011 ASCO Annual Meeting  
   Abstract No: 3041  
   First Author: A. R. Tan  
   Category: Developmental Therapeutics - Experimental Therapeutics - DNA Repair and Apoptosis

3. **Phase I study of at-101 (R-(-)-gossypol) in combination with paclitaxel (P) and carboplatin (C) in solid tumors including castrate-resistant prostate cancer (CRPC).**
   
   Meeting: 2011 Genitourinary Cancers Symposium  
   Abstract No: 169  
   First Author: Y. Zhao  
   Category: Genitourinary Cancer - Prostate Cancer
Presentations by R. A. Moss:

1. A phase I open-label study using lenalidomide and docetaxel in androgen independent prostate cancer (AIPC).
   
   Meeting: 2007 Prostate Cancer Symposium
   Presenter: Rebecca A Moss, MD
   Session: General Poster Session A (General Poster Session)

More...

Educational Book Manuscripts by R. A. Moss:

No items found.